JUL 1 0 2003

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

kinder the Paper Reduction Act of 1995,	no person	ns are required to respond to a collection	n of info	ormation unless it displays a valid OMB control number	
DEMARK		Application Number	08/07	71,052	
TRANSMITTAL		Filing Date	Jun 4, 1993		
FORM (to be used for all correspondence after initial filing)		First Named Inventor Jeffry W. Kreamer		y W. Kreamer	
		Art Unit	1617		
		Examiner Name	T. C	riares TEO. 14	
Total Number of Pages in This Submission 5		Attorney Docket Number	4673	120/4650 CENT	
	FNC	LOSURES (check all that a	nnlv)	riares TECHCENT 4	
Fee Transmittal Form Fee Attached  X Amendment / Reply After Final Affidavits/declaration(s)  Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/		Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attomey, Revocation Change of Correspondence Addres Terminal Disclaimer  Request for Refund  CD, Number of CD(s)		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information  Status Letter  X Other Enclosure(s) (please identify below):  Return Postcard	
Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Daniel A. Rosenberg		,			
Signature David Alosynus					
Date July 7, 2003					
C	ERTIFI	CATE OF TRANSMISSION/M	AILIN	IG	
hereby certify that this correspondence is being far rst class mail in an envelope addressed to: Commi				United States Postal Service with sufficient postage as July 7, 2003	
ype or printed Kristen T. McKen	1				
Signature OSLO	1 Y	nson	Da	ate July 7, 2003	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. Washington, DC 20231.

OIPE	· · · · · · · · · · · · · · · · · · ·	# 40/0
JUL 1 0 2003	IN THE UNITED STATES PAT	ENT AND TRADEMARK OFFICE  OFFI
RADEMARK	In re Application of	Group Art Unit 1617
	Jeffry W. Kreamer	
	Serial No. 08/071,052 Filed: June 4, 1993 For: ASPIRIN AND VITAMIN AND/OR TRACE ELEMENT COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE	Examiner: T. Criares

## **AMENDMENT**

Dear Sir:

In the matter of the above-identified application for United States Letters Patent, and in response to the Office Action mailed May 7, 2003, kindly enter the following amendments and consider the following remarks relative to consideration of the present application.

**AMENDMENT** 

In the claims:

Kindly delete claims 27 and 28.

## **REMARKS**

The Examiner requests that claims 27 and 28 be cancelled, as they were replaced and given new numbers 30 and 31. Applicant's amendment conforms to this request.

Claims 29-31 are rejected under 35 U.S.C. 102 (a) and (f) as anticipated by the unpublished observational study conducted by the University of Southern California and